By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Protalix Biotherapeutics, Inc. 

2 Snunit Street, Science Park
P.O. Box 455
Karmiel    21000  Israel
Phone: 972-4-988-9488 Fax: 972-4-988-9489


SEARCH JOBS








Company News
Protalix Biotherapeutics, Inc. (PLX) Names Shlomo Yanai As Chairman Of The Board Of Directors 7/24/2014 10:09:41 AM
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/27/2014 8:53:11 AM
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014 7:36:02 AM
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014 8:59:08 AM
Protalix Biotherapeutics, Inc. (PLX) CEO Will Retire This Year 6/13/2014 7:42:12 AM
Protalix Biotherapeutics, Inc. (PLX) Announces ELELYSO™ (Taliglucerase Alfa) Approved In Canada For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients 5/30/2014 7:00:49 AM
Protalix Biotherapeutics, Inc. (PLX) To Present At Two Upcoming Healthcare Conferences 5/28/2014 9:53:53 AM
Protalix Biotherapeutics, Inc. (PLX) Announces ELELYSO™ (Taliglucerase Alfa) Approved In Australia For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients 5/22/2014 9:32:26 AM
Protalix Biotherapeutics, Inc. (PLX) To Present At The Oppenheimer 15th Annual Israeli Conference And The Mixiii Israel Innovation Conference, Biomed 5/7/2014 9:23:58 AM
Protalix Biotherapeutics, Inc. (PLX) Announces Data On Oral Antitnf To Be Presented At Digestive Disease Week 2014 Meeting 4/23/2014 9:15:31 AM
12345678910...
//-->